Cyclophosphamide (CY) combined with granulocyte colony-stimulating factor (G-CSF) is commonly used to mobilise blood progenitor cells to support high-dose therapy in patients with multiple myeloma (MM). The optimal dose of CY in this setting is unknown. We have retrospectively analysed mobilisation efficiency and need for supportive care in 57 patients with newly diagnosed myeloma previously treated with VAD7local radiotherapy. The patients were mobilised either with low-dose CY
tion; efficiency; toxicity; multiple myeloma Patients with multiple myeloma (MM) have a median survival of 3-4 years with conventional chemotherapy. In a randomised trial, high-dose therapy supported by stem cell rescue was superior over conventional chemotherapy in terms of complete remission rate, progression-free survival and overall survival. 1 The superiority of single or tandem autotransplants over conventional therapy has also been suggested in some controlled studies. 2, 3 More than 95% of autotransplants for MM are now performed with the support of blood progenitor cells. 4 High-dose (7 g/m 2 ) cyclophosphamide (CY) alone or combined with a growth factor was initially used for mobilisation of progenitor cells in myeloma patients. [5] [6] [7] Goldschmidt et al 8 found that CY 7 g/m 2 plus G-CSF was superior to CY 4 g/m 2 plus G-CSF in this regard. However, high-dose CY is associated with significant toxicity. 7, 9 Recently, Fitoussi et al 9 showed that intermediate-dose CY (ID-CY) (4 g/m 2 ) plus growth factor was equally effective as high-dose CY in mobilising progenitor cells in myeloma patients but was less toxic.
Mobilisation with CY 4 g/m 2 plus G-CSF is, however, also associated with significant toxicity and need for supportive care. We hypothesised whether low-dose CY (LD-CY) (up to 2 g/m 2 ) could be as effective and, less toxic mobilisation regimen in patients with newly diagnosed MM. Therefore, a retrospective analysis in myeloma patients previously treated only with VAD7radiotherapy who were then mobilised either with LD-CY+G-CSF or ID-CY+G-CSF was carried out.
Patients and methods

Patients
From prospectively collected databases held at the Departments of Medicine, Turku University Central Hospital and Kuopio University Hospital, patients with newly diagnosed multiple myeloma, who had been treated only with VAD chemotherapy7radiotherapy before the progenitor cell mobilisation, were included in this analysis. The patients fulfilling this criteria and mobilised with CY 1. Progenitor cell mobilisation LD-CY protocol was used during the study period in Turku University Central Hospital (TUCH). The CY dose was 1.2 g/m 2 in nine patients, 1.5 g/m 2 in 12 patients, 1.7 g/ m 2 in one patient, 1.8 g/m 2 in one patient and 2 g/m 2 in two patients. CY was given in a 60 min infusion on day 0 followed by MESNA. G-CSF (5-10 mg/kg/day) was started on day +1 and continued until the completion of apheresis. The patients were rehospitalised on day +8, and blood CD34+ counts were measured daily from day +9 onwards. When the blood CD34+ cell count was 420 Â 10 6 /l, apheresis was started. 10, 11 ID-CY was used in Kuopio University Hospital (KUH) during the study period. The CY dose was 4 g/m 2 in all patients and was given in a 90 min infusion with cardiac monitoring on day 0 followed by MESNA. Intravenous hydration (6 l/day) was used for 2 days. G-CSF (5 mg/kg/ day) was started on day +2 and continued until the completion of apheresis. The patients were routinely rehospitalised on day +8. Blood CD34+ count was measured on day +9 and apheresis was started if B-CD34+ count exceeded 20 Â 10 6 /l.
CD34+ cell enumeration
In both hospital laboratories, the CD34+ cells in peripheral blood and apheresis products were enumerated with commercial single-platform reagent kits. In TUCH, PE-conjugated class III monoclonal antibody 8G12 and prealiquoted True Count internal standard tubes from Becton Dickinson, San Jose, CA, USA, and in KUH, the StemKit CD34+ HPC Enumeration Kit from Coulter/ Immunotech, France, were used. Sequential gating according to the ISHAGE guidelines was performed in both laboratories. The methods fulfilled the criteria for adequate performance in UK National Quality Assessment Scheme (UK NEQAS).
The interlaboratory coefficient of variation analysed from the NEQAS external quality control samples was 8.8% and the correlation coefficient between the determinations made in the two laboratories (TUCH and KUH) was 0.984 (Po0.001).
Apheresis
In TUCH, leukaphereses were performed using a Fenwal CS-3000 Plus device (Baxter Healthcare Corp., Deerfield, IL, USA) and also since 2000 a COM.TEC (Fresenius HemoCare GmbH, Bad Hamburg, Germany) device. The minimum target yield for an adequate transplant was 2 Â 10 6 /kg CD34+ cells. Patientso60 years of age were included in the institutional double-transplant protocol with CD34+ cell selected grafts. The prerequisite to proceed to CD34+ selection was the minimum harvest of 5 Â 10 6 /kg CD34+ cells on two consecutive days. Whole blood flow rate was 50-70 ml/min, and a total of 10 l of blood was run for each collection.
In KUH, all collections were performed with a COBE SPECTRA cell separator (Denver, CO, USA). A volume of 10-14 l of blood was processed during 3-4 h. The target of the collection was at least 2 Â 10 6 /kg CD34+ cells to support a single course of high-dose therapy with an unselected graft.
The final products were frozen in 10% DMSO (final concentration) under computer control with a cryopreservation device (Kryo 10, Planer, Sunbury-on-Thames, UK). In TUCH, the frozen products were stored in À1961C in liquid nitrogen and in KUH in À1401C electric freezer with liquid nitrogen back-up.
Data collection
Demographic data, myeloma isotype, Durie-Salmon stage and therapy before the progenitor cell mobilisation were recorded for every patient. Of the postmobilisation factors, the highest blood CD34+ cell count measured, time from CY infusion to the highest blood CD34+ cell counts, as well as the yield of the first apheresis was collected. Also, the need for supportive care (parenteral antibiotics, blood products) as well as hospital days during the mobilisation and apheresis phases were recorded. A successful mobilisation was defined as a collection of at least 2 Â 10 6 /kg CD34+ cells after a single mobilisation attempt. Data on engraftment were also analysed in all patients.
Statistical analysis
All calculations were performed with SPSS/PC statistical program (version 9.0, SPSS Inc., Chicago, IL, USA). For the comparison of continuous variables between the LD-CY and ID-CY groups, Mann-Whitney U-test was used. w 2 test was used for the comparison of nominal data. P values o0.05 were considered statistically significant. (Table 1) LD-CY and ID-CY groups were comparable with regard to age, sex and Durie-Salmon stage at diagnosis. In the ID-CY group, previous local radiotherapy was more frequent and the patients had received a median of one VAD cycle more before progenitor cell mobilisation. Responses to first-line chemotherapy were comparable between the groups. In the LD-CY group, 24 patients received filgrastim and one patient lenograstim after the CY infusion. All patients in the ID-CY group received filgrastim. The median dose of G-CSF was 7 mg/kg/day (range 4-10) in the LD-CY group and 5 mg/kg/day (range 3-10) in the ID-CY group (Po0.001).
Results
Patient characteristics
Mobilisation efficiency (Table 2)
In 56 out of 57 myeloma patients (98%), a minimum yield of at least 2 Â 10 6 /kg CD34+ cells was harvested. One patient (4%) in the LD-CY group failed the progenitor cell mobilisation (peak blood CD34+ count 5 Â 10 6 /l) vs none in the ID-CY group.
The highest blood CD34+ cell counts were reached earlier in the LD-CY group. The first apheresis yielded at least 2 Â 10 6 /kg CD34+ cells in 88% and 84% of the
No statistical differences were observed in the median yield of the first collection.
Toxicity and need for supportive care (Table 3) ID-CY was associated with higher toxicity as assessed with frequency of fever and need for supportive care. Also, more days spent in hospital were observed in this patient group during mobilisation and apheresis. In fact, 12 out of 25 patients mobilised with LD-CY (48%) spent only 1 day at hospital during the mobilisation and can thus be regarded as outpatients.
High-dose therapy and engraftment
All patients who were successfully mobilised proceeded to high-dose therapy, which consisted either of high-dose melphalan (200 mg/m 2 ) or a combination of total body irradiation (12 Gy) and melphalan (140 mg/m 2 ). All patients received G-CSF after the progenitor cell infusion starting on day +4-5. One patient in the LD-CY group died early before engraftment (day +9). All other patients engrafted. While no differences were observed in the time to reach neutrophils 40.5 Â 10 9 /l, the platelet engraftment was slower in the LD-CY group (Table 4) .
Discussion
This retrospective analysis shows that progenitor cell mobilisation is almost always successful in myeloma patients who have received only VAD+/À radiotherapy prior to mobilisation. The most important finding is that LD-CY (1.2-2 g/m 2 ) plus G-CSF was as effective as ID-CY (4 g/m 2 ) in terms of adequate progenitor cell mobilisation, but was associated with less toxicity and less need for supportive care. These observations are important both in view of optimal management of myeloma patients recruited into high-dose therapy protocols as well as optimising resource utilisation and costs.
Patient characteristics have a major impact in the analysis of factors related to progenitor cell mobilisation. 12 Several factors have been associated with progenitor cell yields in myeloma patients, [13] [14] [15] [16] but prior treatment with melphalan is especially important in this respect. Variations in previous therapy might have an important impact on the comparison of various mobilisation regimens. In our Low
analysis the groups were comparable, although some differences existed with regard to previous radiotherapy and number of previous VAD cycles. In addition, the patients mobilised with LD-CY had higher filgrastim doses. Both regimens proved to be very effective in mobilising progenitor cells. Only one patient failed to mobilise sufficiently to proceed to high-dose therapy. Although the blood CD34+ cell counts were higher after mobilisation with LD-CY plus G-CSF, this does not imply that this regimen is superior with regard to mobilisation efficiency. In addition to somewhat more favourable patient characteristics and higher filgrastim doses, differences in the mobilisation kinetics between these regimens are perhaps even more important. Patients mobilised with LD-CY plus filgrastim were collected at a later phase of mobilisation as suggested by significantly higher leucocyte counts at the start of apheresis. On the other hand, patients mobilised with ID-CY plus G-CSF were apheresed often on the rising part of progenitor cell mobilisation, since blood CD34+ cell counts were frequently higher on the day after the apheresis.
If mobilisation regimens are about equally effective, toxicity remains an even more important issue. In this respect, LD-CY regimen is clearly superior to ID-CY. Nearly half of our patients in the LD-CY group needed only one hospital day during the mobilisation and can thus be regarded as outpatients. Only a minority of the patients mobilised with LD-CY needed any supportive therapy. Also, nausea and vomiting are likely to be less frequent and less severe in patients receiving lower doses of CY but were not formally assessed in this retrospective analysis. Thus, significant cost savings associated with the use of the LD-CY regimen seem obvious.
Growth factors alone are also effective in the progenitor cell mobilisation in myeloma patients. [17] [18] [19] Two randomised trials suggest that CY (4 g/m 2 or 6 g/m 2 ) plus a growth factor is more effective in progenitor cell mobilisation in myeloma patients than G-CSF alone, but at the expense of increased toxicity. 17, 20 However, both these studies suggested that adequate collections can be achieved in the majority of the patients with G-CSF (10 or 16 mg/kg/day) alone. It is, however, unknown whether the benefits of lower toxicity of G-CSF are offset by higher number of aphereses needed to reach the target yields or by higher myeloma cell contamination of the grafts.
Our analysis has limitations. Differences in patient characteristics might have some influence on the analysis of mobilisation efficiency between these regimens, but are obviously less important with regard to the analysis of toxicity and need for supportive care. Finally, the conclusions of mobilisation efficiency apply only to newly diagnosed myeloma patients cytoreduced with VAD chemotherapy7local radiotherapy. Primary refractory patients with heavy marrow infiltration and/or patients who have received several courses of melphalan or other stem cell toxic agents are more difficult to mobilise. At present, data are lacking on the efficiency of LD-CY plus G-CSF in this patient group.
To conclude, LD-CY followed by G-CSF is as effective as ID-CY plus G-CSF in terms of adequate progenitor cell mobilisation to support high-dose therapy in newly diagnosed myeloma patients, but the low-dose regimen is associated with less toxicity and need for supportive care. A significant proportion of the patients can be mobilised as outpatients with this regimen. Therefore, LD-CY+G-CSF is superior with regard to patient preference as well as in terms of optimal resource utilisation. /l (day), median (range) 11 (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) 11 (7) (8) (9) (10) (11) (12) (13) (14) Platelets >20 Â 10 9 /l (day) median (range) 13 11.5 (9-15) Po0.001
a Mobilisation failure. HD-MEL, high-dose melphalan (200 mg/m 2 ); TBI-MEL, total body irradiation (12 Gy) plus melphalan (140 mg/m 2 ).
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